FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

• click to rate

  Posted by Two Blokes Jul 14 - Filed in Stock - 1 view
  
  Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.